EP3578204 - CONJUGATE OF BIOACTIVE MATERIAL HAVING ENHANCED SUSTAINABILITY AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.11.2019 Database last updated on 24.08.2024 | |
Former | The international publication has been made Status updated on 11.08.2018 | Most recent event Tooltip | 19.02.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Hanmi Pharm. Co., Ltd. 214 Muha-ro Paltan-myeon Hwaseong-si, Gyeonggi-do 18536 / KR | [2019/50] | Inventor(s) | 01 /
PARK, Young Jin 550 Dongtangiheung-ro Hwaseong-si Gyeonggi-do 18469 / KR | 02 /
LEE, Jong-Soo 550 Dongtangiheung-ro Hwaseong-si Gyeonggi-do 18469 / KR | 03 /
CHOI, In Young 550 Dongtangiheung-ro Hwaseong-si Gyeonggi-do 18469 / KR | [2019/50] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
Former [2019/50] | Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | Application number, filing date | 18748653.5 | 02.02.2018 | [2019/50] | WO2018KR01458 | Priority number, date | KR20170015663 | 03.02.2017 Original published format: KR 20170015663 | KR20170127187 | 29.09.2017 Original published format: KR 20170127187 | [2019/50] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018143729 | Date: | 09.08.2018 | Language: | KO | [2018/32] | Type: | A1 Application with search report | No.: | EP3578204 | Date: | 11.12.2019 | Language: | EN | [2019/50] | Search report(s) | International search report - published on: | KR | 09.08.2018 | (Supplementary) European search report - dispatched on: | EP | 04.12.2020 | Classification | IPC: | A61K47/68, A61K47/60, A61K38/28, A61P1/18, A61P3/10, A61P5/48, A61P5/50 | [2021/01] | CPC: |
A61K38/28 (EP,KR,US);
A61K47/60 (EP,KR,US);
A61K47/68 (EP);
A61K47/6801 (US);
A61K47/6803 (KR);
A61K47/6811 (KR);
A61K47/6889 (KR);
A61P1/18 (EP);
A61P3/10 (EP);
|
Former IPC [2019/50] | A61K47/60, A61K47/68, A61K38/28 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/50] | Title | German: | KONJUGAT AUS BIOAKTIVEM MATERIAL MIT ERHÖHTER BESTÄNDIGKEIT UND VERWENDUNG DAVON | [2019/50] | English: | CONJUGATE OF BIOACTIVE MATERIAL HAVING ENHANCED SUSTAINABILITY AND USE THEREOF | [2019/50] | French: | CONJUGUÉ DE SUBSTANCE BIOACTIVE AYANT UNE DURABILITÉ AMÉLIORÉE ET SON UTILISATION | [2019/50] | Entry into regional phase | 14.08.2019 | Translation filed | 14.08.2019 | National basic fee paid | 14.08.2019 | Search fee paid | 14.08.2019 | Designation fee(s) paid | 14.08.2019 | Examination fee paid | Examination procedure | 14.08.2019 | Examination requested [2019/50] | 29.06.2021 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 19.02.2020 | Renewal fee patent year 03 | 19.02.2021 | Renewal fee patent year 04 | 09.02.2022 | Renewal fee patent year 05 | 21.02.2023 | Renewal fee patent year 06 | 19.02.2024 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2008082274 (HANMI PHARMACEUTICAL CO LTD [KR], et al) [X] 1-6,11-15 * examples 1-12; paragraph 115; claim 21, 33. *; | [X]KR20110134209 (HANMI HOLDINGS CO LTD [KR]) [X] 1-15 * embodiments 10-12, paragraph 65, claim 10, 16 *; | [X]CA2913886 (HANMI PHARM IND CO LTD [KR]) [X] 1-6,11-14 * example 1 *; | [X]CA2950266 (HANMI PHARM IND CO LTD [KR]) [X] 1-15 * examples 8 -11, claims 23-26, page 17-18 *; | [XD]WO2015183054 (HANMI PHARM IND CO LTD [KR]) [XD] 1-15 * example 8, paragraph 64, claim 1, 12, 20 *; | [X]WO2015186988 (HANMI PHARM IND CO LTD [KR]) [X] 1-6,11-15* example 3, paragraph 118 and 149, page 19 *; | [X]EP2963056 (HANMI PHARM IND CO LTD [KR]) [X] 1-15 * examples 8-11, paragraph 74, claim 17 and 23 *; | [X]EP3098235 (HANMI PHARM IND CO LTD [KR]) [X] 1-15 * examples 8-11; paragraph 99 and 128, claim 30 and 32 *; | [X]CA2991107 (HANMI PHARM IND CO LTD [KR]) [X] 1-6,11-15 * example 6; paragraph 420; claim 28, 32 *; | [AP]WO2017052321 (HANMI PHARM IND CO LTD [KR]) [AP] 1-15 * whole document, in particular paragraph [0208] *; | [XP]WO2017052329 (HANMI PHARM IND CO LTD [KR]) [XP] 1-14 * examples 1, 2, 3+7, 4, 5, 6, 11; paragraph 125, claim 9 *; | [XP]WO2018004283 (HANMI PHARM IND CO LTD [KR]) [XP] 1-6,11-15 * example 6; paragraph 205 and 208; claim 31 and 51 *; | [E]WO2018105988 (HANMI PHARM IND CO LTD [KR]) [E] 1-14 * preparation example 1, section (1)-(3); paragraph 93 *; | [E]EP3341025 (HANMI PHARM IND CO LTD [KR]) [E] 1-14; | EP3354664 [ ] (HANMI PHARM IND CO LTD [KR]); | [E]WO2018174668 (HANMI PHARM IND CO LTD [KR]) [E] 1-15 * the whole document *; | [E]WO2019066603 (HANMI PHARM IND CO LTD [KR]) [E] 1-15 * the whole document *; | [E]EP3479841 (HANMI PHARM IND CO LTD [KR]) [E] 1-6,11-15; | [E]EP3549950 (HANMI PHARM IND CO LTD [KR]) [E] 1-14; | EP3604328 [ ] (HANMI PHARM IND CO LTD [KR]); | EP3689914 [ ] (HANMI PHARM IND CO LTD [KR]) | International search | [X]KR20080064750 (HANMI PHARM IND CO LTD [KR]) [X] 1-6, 12-18* See paragraphs [0011], [0053], [00601; and claims 1-33. *; | [X]KR20110134209 (HANMI HOLDINGS CO LTD [KR]) [X] 1-8, 12-18 * See paragraphs [0031], [0065]; and claims 1-20. *; | [X]KR20150087130 (HANMI PHARM IND CO LTD [KR]) [X] 1-18 * See paragraph [0080]; example 8; and claims 1-32. *; | [X]KR20150138101 (HANMI PHARM IND CO LTD [KR]) [X] 1-18 * See paragraphs [0034]. [0046]. [0089]; example 8; and claims 1-18. *; | [X]KR20160001391 (HANMI PHARM IND CO LTD [KR]) [X] 1-14, 17-18 * See claims 1-17. *; | [X]KR20160007295 (HANMI PHARM IND CO LTD [KR]) [X] 1-14, 17-18 * See paragraphs [0055], [0056], [0084]; and claims 1-20. *; | [X]KR20170003466 (HANMI PHARM IND CO LTD [KR]) [X] 1-7, 12-18 * See paragraphs [0167], [0420]; examples 5, 6; and claims 1-45. * | by applicant | WO9632478 | WO9734631 | WO0104329 | KR20010009171 | KR20090008151 | WO2009011544 | WO2012169798 | KR20120137271 | KR20120139579 | WO2012173422 | KR20140106452 | WO2015108398 | KR20150087130 | WO2015183054 | WO2016043533 | WO2016108586 | WO2017003191 | KR20170026284 | WO2017039267 | WO2017116205 | WO2017116204 | - AUTHIER F et al., Biochem J., (19980601), vol. 332, pages 421 - 30 | - DUCKWORTH WC et al., Endocr Rev., (19981000), vol. 19, no. 5, pages 608 - 24 | - VALERA MORA ME et al., J Am Coll Nutr, (20031200), vol. 22, no. 6, pages 487 - 93 |